Array BioPharma ARRY announced that Francis Bullock, Ph.D., and
Kevin Koch, Ph.D., have decided not to stand for reelection to its Board of
Directors and that David Snitman, Ph.D., intends to resign from the Board of
Directors. Each of the directors will be leaving the Board effective following
Array's Annual Meeting of Stockholders to be held on October 24, 2012. Dr.
Koch and Dr. Snitman will continue their leadership roles on Array's executive
team, with Dr. Koch continuing to serve as President and Chief Scientific
Officer and Dr. Snitman continuing to serve as Chief Operating Officer and
Vice President of Business Development. Dr. Bullock decided not to stand for
reelection so that he could devote more time to his other personal and
professional responsibilities. A search is underway to add independent
directors with industry knowledge, skills and expertise to guide Array in
achieving its goal of becoming a commercial-stage biopharmaceutical company.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsManagement
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in